

Asthma and urticaria-omalizumab



Accompaniment to
the mastery of omalizumab prescription
in France: Provence Alpes Cote d'Azur and
Corsica regions in 2017

Monoclonal antibodies omalizumab (Xolair *)

Omalizumab is effective

In severe asthma

- not mastered
- And IgE dependant

In chronic urticaria

- escaping the massive prescriptions
of antihistamines

Monoclonal antibodies omalizumab (Xolair *)

Purpose of the study

- ✓ Analyse if the prescriptions correspond in practice to the product recommendations
- ✓ Diseases out of the field of recommendations
- ✓ Look at the effect of our study on the reduction of inappropriated prescriptions during following year.

Monoclonal antibodies omalizumab (Xolair *)

Materiels and Methods

**1-We conduct two preliminary experiments in
Arles and Martigues (june2016)**

**2- And then extension of the survey in Provence
Alpes Cote d'Azur and Corsica regions
(PACA and Corsica)**

Monoclonal antibodies omalizumab (Xolair *) Materiels and Methods

For ARLES = little ancien city of Camargue

53000 inhabitants

the most extensive French commune

poor population, an hospital

***For MARTIGUES = little town city of the pond
of Berre***

50000 inhabitants

strong development

an hospital also

**omalizumab (Xolair *)
experiment for Asthma indications
in Arles and Martigues hospital centers**

During 2016 year:

- ✓ *Meeting with the head of the department of pneumology .(one for each hospital)*
- ✓ *a team composed of a medical consultant,(one for Martigues and two for Arles) and a pharmacist for each hospital.*

Each omalizumab prescription of the hospital was analyzed in common.

Monoclonal antibodies omalizumab (Xolair *)

Materiels and Methods

**1-Two preliminary experiments in Arles and
Martigues**

**2- Extension of the survey in PACA and Corsica
(from september 2017- january 2018)**

omalizumab (Xolair *)
experiment for *Asthma* indications in Paca and Corsica hospital centers

first step

- ❑ *Analysis, by request of the prescription for all pulmologists and dermatologists of the region*
- ❑ *Both in the hospital and for prescribers in the city*

Selection criteria for pulmologists

Volume of prescription .

Number of patients .

Financial volume committed (obligatorily higher than 25000 euros) .

Progression between 2016 and 2017 (greater than 15%) .

22 pulmologists in hospitals and private practice was selected

omalizumab (Xolair[®])

experiment for *Asthma* indications in PACA and
Corsica : preparation

Second step

The « mission risk management » product :

global summary sheet,

analysis of each patient

restitution of each commented request.

the same operator analyze each prescriber,
and all of these patients

Validation : Regional Director

omalizumab (Xolair[®])

experiment for *Asthma* indications in PACA and Corsica : preparation

Third step

Bring together a team of pharmacists- physicians of our departement

The purpose was to meet the selected 22 pulmologists to restitute their activity and discuss the medical indications for prescribing OMALIZUMAB in asthma

omalizumab (Xolair *)
experiment for *Asthma* indications in PACA and Corsica hospital centers

analysis equipment

- >a file for each prescriber(from 2 to 14)**
- >a file for each hospital with sub-file for each prescriber(from 4 to 25)**
- >the patients concerned for each prescriber**
 - the seniority of the prescription**
 - the ancillary medication prescriptions**
 - the acts performed, and the context**
 - payment (daily allowance)**
 - common classification of medical acts**
 - list of products and services**

omalizumab (Xolair *)

experiment for *Asthma* indications in PACA and Corsica hospital centers

Meeting

- Meetings lasted from 30 minutes to one thirty
 - Mode of medicalized accompaniment
- > By health professional relations network components after training; with a fact sheet of recommendations to make documents produced by the analyst (summary, analysis and request)
minimum of two files were required, more than 5 solicited
all the prescriptions could be discussed

omalizumab (Xolair *)
experiment for *Urticaria* indications in PACA and
Corsica hospital centers

For Dermatologists

Selection criteria for dermatologists

Same criterias as for pulmologists

Except Financial volume committed (obligatorily higher than 12000 euros) and no progression between 2016 and 2017

9 dermatologists were selected

omalizumab (Xolair *)
experiment for Asthma and Urticaria indications in
PACA and Corsica hospital centers

The three steps of the study done
for asthma where the same as done
for urticaria

Monoclonal antibodies omalizumab (Xolair *)

Results

**1- For two preliminary experiments in Arles and
Martigues**

**2- And then extension of the survey in Provence
Alpes Cote d'Azur and Corsica regions
(PACA and Corsica)**

omalizumab (Xolair *)

Accompanying experiments-results

In ARLES

2 pulmonologists

100% inappropriated prescriptions

50% decrease in the first trimester

25% decrease in the year

the number of patients falling (44 to 32)

In MARTIGUES

1 pulmonologist

70% inappropriated prescriptions

15% decrease in the year

Monoclonal antibodies omalizumab (Xolair *)

Results

- 1- For two preliminary experiments in Arles and Martigues
- 2- For the extension of the survey in Provence Alpes Cote d'Azur and Corsica regions (PACA and Corsica)

omalizumab (Xolair *)

results of accompaniment- pulmonologists

22 pulmonologists

- 55% inappropriated prescriptions
- Bad stage of asthma (stage 1 or 2 and not stage 4 exceeded or 5)
- Prescriptions for chronic obstructive broncho-pulmonary disease
- Not allergic asthma
- No IgE measurement

omalizumab (Xolair *) - analysis

Accompaniment finding = Pulmonologists

- **22 pulmonologists**

- ✓ **0% to 80% decrease in the year (mean 8%)**
- ✓ **15 pulmonologists decrease the inappropriated prescriptions**
- ✓ **7 pulmonologists continued an ascending prescription**

omalizumab (Xolair *)

results of accompaniment- dermatologists

- **8 dermatologists**
- **90% inappropriated prescriptions**
- ✓ **No prescription antihistamine before prescribing Omalizulab**
- ✓ **Confusion between chronic urticaria and irreducible pruritus**

omalizumab (Xolair *)

Global results of accompaniment

✓ ***Success of the study with significant decrease of inappropriate prescriptions in asthma***

✓ ***Failure of the study as concerning the inappropriate prescriptions in urticaria***

Monoclonal antibodies omalizumab (Xolair *) – Conclusions- real reasons

Reasons for

inappropriated prescriptions in asthma

- ✓ *Prescribers admit having especially tried a new therapeutic*
- ✓ *Doctors discover that their patient did not use previous treatments*
- ✓ *Doctors are known to have extended the indications according to their needs*

Monoclonal antibodies omalizumab (Xolair *)

Conclusions - tomorrow

- ✓ *the prescriptions should be analyzed regularly with a pre-established protocol(High Authority in Health published recommendations)+ Regional Health Agency*
- ✓ *Final purpose: only appropriate indications should be taken in charge by the health care institution*

